{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:45:02Z","timestamp":1761518702197},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,9,1]]},"abstract":"<jats:p> PURPOSE: Theoretical considerations and clinical experience suggest that dose-dense chemotherapy may be superior to other approaches using the same drugs. We studied a dose-dense combination of doxorubicin and cyclophosphamide, with or without fluorouracil, as adjuvant therapy. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients with resected breast cancer were treated if they were node-positive and estrogen receptor\u2013negative, positive for overexpression of Her-2-neu, or had four or more involved nodes. Doxorubicin was given weekly to a total dose of 480 mg\/m<jats:sup>2<\/jats:sup>. Cyclophosphamide 60 mg\/m<jats:sup>2<\/jats:sup> was given daily by mouth during the period of doxorubicin treatment. The first 30 patients received fluorouracil at 300 mg\/m<jats:sup>2<\/jats:sup>\/wk intravenously concurrently with doxorubicin administration. In the last 22, it was omitted because of symptomatic hand-foot syndrome in the majority of patients. Filgrastim (granulocyte colony-stimulating factor [G-CSF]) was administered during chemotherapy every day except the day of intravenous administration and continued until 1 week after the completion of the chemotherapy. <\/jats:p><jats:p> RESULTS: Between October 20, 1992, and June 10, 1997, we enrolled 52 patients. The mean delivered dose-intensity for doxorubicin was 18.6 mg\/m<jats:sup>2<\/jats:sup>\/wk. Hospitalization was required in 6% of patients for reversible febrile neutropenia. There were no acute treatment-related deaths, but one patient subsequently died of acute leukemia with a characteristic translocation for anthracycline-related exposure. At 5 years, the event-free survival was 86% for all patients (95% confidence interval, 75% to 95%). <\/jats:p><jats:p> CONCLUSION: Continuous dose-dense chemotherapy with G-CSF support produced encouraging results, which seem to be superior to those expected with \u201cstandard\u201d doxorubicin and cyclophosphamide chemotherapy. It deserves a test in the form of a randomized trial where this approach to anthracycline-based treatment is compared with intermittent administration. <\/jats:p>","DOI":"10.1200\/jco.2002.12.113","type":"journal-article","created":{"date-parts":[[2002,8,29]],"date-time":"2002-08-29T19:45:09Z","timestamp":1030650309000},"page":"3637-3643","source":"Crossref","is-referenced-by-count":44,"title":["Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer"],"prefix":"10.1200","volume":"20","author":[{"given":"Georgiana K.","family":"Ellis","sequence":"first","affiliation":[{"name":"From the Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Livingston","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Gralow","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie J.","family":"Green","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tove","family":"Thompson","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-113025","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940801)74:3+<1177::AID-CNCR2820741529>3.0.CO;2-7"},{"key":"R2-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1162"},{"key":"R3-113025","unstructured":"Norton  L:   Adjuvant breast cancer therapy:  Current status and future strategies-growth kinetic and the improved drug therapy of breast cancer.   Semin Oncol 26:  1,1999-4,     (suppl 3)"},{"key":"R4-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1118"},{"key":"R5-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.93"},{"key":"R6-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1395"},{"key":"R7-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1407"},{"key":"R8-113025","unstructured":"Gralow  JR,   Ellis  GK,   Williams  MA,  et al:  Docetaxel + vinorelbine with concurrent G-SCF support:  Phase II study in stage IV breast cancer.   Proc Am Soc Clin Oncol 19:  106a,2000  (abstr 410)"},{"key":"R9-113025","unstructured":"Ellis  GK,   Green  SJ,   Livingston  RB,  et al:  Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a southwest oncology group phase II study.  Proc Am Soc Clin Oncol 19:  85a,2000  (abstr 326)"},{"key":"R10-113025","unstructured":"Rowley  JD,   Reshmi  S,   Sobulo  O,  et al:  All patients with the t(11:  16)(q23;p13.3) that involves MLL and CBP have treatment related hematologic disorders.   Blood 90:  535,1997-541,"},{"key":"R11-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2722"},{"key":"R12-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.12.1640"},{"key":"R13-113025","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701526"},{"key":"R14-113025","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.4710"},{"key":"R15-113025","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530110624"},{"key":"R16-113025","doi-asserted-by":"crossref","unstructured":"Hryniuk  W,   Bush  H:   The importance of dose-intensity in chemotherapy of metastatic breast cancer.  J Clin Oncol 2:  1162,1986-1170,","DOI":"10.1200\/JCO.1986.4.8.1162"},{"key":"R17-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1858"},{"key":"R18-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3374"},{"key":"R19-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.599"},{"key":"R20-113025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.21.3651"},{"key":"R21-113025","unstructured":"Green  MC,   Buzdar  AU,   Smith  T,  et al:  Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial.  Proc Am Soc Clin Oncol 20:  33a,2001  (abstr 129)"},{"key":"R22-113025","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D"},{"key":"R23-113025","unstructured":"Kuerer  HM,   Newman  LA,   Buzdar  AU,  et al:  Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.  Cancer J Sci Am 4:  230,1998-236,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.12.113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:53:22Z","timestamp":1653515602000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.12.113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,1]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2002,9,1]]}},"alternative-id":["10.1200\/JCO.2002.12.113"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.12.113","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,1]]}}}